This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Scopus Google Scholar Articles by Peters, S. Articles by Richter, C. PubMed PubMed Citation Articles by Peters, S. Articles by Richter, C. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Social Bookmarking                         What's this?

First-in-man use of polymer-free valsartan-eluting stents in small coronary vessels: a comparison to polymer-free rapamycin (2%)-eluting stents

Klinikum gGmbH Quedlinburg, Cardiology, Germany, ste.peters{at}asklepios.com

Boris Behnisch

Translumina GmbH, Hechingen, Germany

Torsten Heilmann

Translumina GmbH, Hechingen, Germany

Christian Richter

Translumina GmbH, Hechingen, Germany

Introduction. Orally administered angiotensin receptor antagonists administered after bare-metal stent implantation and even after drug-eluting stent implantation seem to lower in-stent restenosis rates.Whether valsartan-eluting stents are similarly effective was tested here in a first-in-man trial.

Materials and methods. The efficacy of a polymer-free drug-eluting stent coated with 300 mcg valsartan was compared to a coating with a 2% rapamycin solution in small ( 2.5 mm) coronary vessels with and without oral valsartan on the basis of the YUKON Choice stent system (Translumina GmbH, Hechingen, Germany). Fifteen patients (eight males, mean age 64.4±7.7 years) were treated with YUKON Choice valsartan-eluting stents and 30 patients (24 males, mean age 65.7±8.4 years) received YUKON Choice rapamycin-eluting stents. Clopidogrel was given for six months in all patients.

Results. Within the first 30 days, no adverse events occurred in either group. Binary in-stent restenosis rate was 30.8% (four in 13 angiographic controls) in the valsartan-eluting stent group and 35.0% (eight in 20 angiographic controls) in the rapamycin-eluting YUKON Choice stent group. Mean late lumen loss was 0.78±0.53 mm and 0.79±0.58 mm, respectively. Target lesion and target vessel revascularisation rate was 26.6% and 25.0%, respectively. No restenoses in rapamycin-eluting YUKON Choice stents appeared in 12 patients with adjunct oral valsartan administration.

Conclusions. If polymer-free YUKON Choice stents are used in small vessels, valsartan-eluting stents show an identical efficacy as rapamycin-loaded stents. In patients with rapamycin-eluting YUKON Choice stents it seems that the efficacy can be increased by oral valsartan administration.

Key Words: drug-eluting stents • in-stent restenosis • polymer-free stent design • valsartan

References

• Stone GW, Moses JW, Ellis SG et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007;356:998-1008.[Abstract/Free Full Text]
• Stettler C., Wandel S., Allemann S. et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007;370:937-48.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Imanishi T., Kobayashi K., Kuki S., Takahashi C., Akasaka T. Sirolimus accelerates senescence of endothelial progenitor cells through telomerase inactivation. Atherosclerosis 2006; 189: 288-96.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Daemen J., Wenaweser P., Tsuchida K. et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007;369:667-78.[CrossRef][Medline] [Order article via Infotrieve]
• Rodriguez-Granillo GA, Valgimigli M., Garcia-Garcia HM et al. One-year clinical outcome after coronary stenting of very small vessels using 2.25 mm sirolimus- and paclitaxel-eluting stents: a comparison between the RESEARCH and T-SEARCH registries. J Invasive Cardiol 2005;17:409-12.[Medline] [Order article via Infotrieve]
• Tanimoto S., Daemen J., Tsuchida K. et al. Two-year clinical outcome after coronary stenting of small vessels using 2.25-mm sirolimus- and paclitaxel-eluting stents: insight into the RESEARCH and T-SEARCH registries. Catheter Cardiovasc Interv 2007;69:94-103.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Togni M., Eber S., Widmer J. et al. Impact of vessel size on outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents: a subgroup analysis of the SIRTAX trial. J Am Coll Cardiol 2007;50:1123-31.[Abstract/Free Full Text]
• Mehilli J., Dibra A., Kastrati A., Pache J., Dirschinger J., Schömig A. Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels. Eur Heart J 2006;27:260-6.[Abstract/Free Full Text]
• Brunner-La Rocca HP, Kaiser C., Bernheim A. et al.; BASKET Investigators. Cost-effectiveness of drug-eluting stents in patients at high or low risk of major cardiac events in the Basel Stent KostenEffektivitäts Trial (BASKET): an 18-month analysis. Lancet 2007;370:1552-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Peters S., Götting B., Trümmel M., Rust H., Brattström A. Valsartan for the prevention of restenosis after stenting of type B2/C lesions: the ValPREST trial. J Invasive Cardiol 2001;13:93-7.[Medline] [Order article via Infotrieve]
• Peters S., Trümmel M., Meyners W., Koehler B., Westermann KU Valsartan versus ACE inhibiton after bare metal stent implantation - results of the VALVACE trial. Int J Cardiol 2005; 98: 331-5.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Peters S. Comparison of efficacy of low (80mg) and high-dose (160-320mg) valsartan in the prevention of in-stent restenosis after implantation of bare-metal stents in type B2/C lesions. Am J Cardiovasc Drugs 2008;8:83-7.[Web of Science][Medline] [Order article via Infotrieve]
• Wang L., Li G., Chen H. et al. Effect of Valsartan-eluting stents on the expression of angiotensin II type 2 receptor. Chinese Med J 2006;119:601-04.
• Hausleiter J., Kastrati A., Wessely R. et al. Prevention of restenosis by a novel drug-eluting stent system with a dose-adjustable, polymer-free, on-site stent coating. Eur Heart J 2005;26:1475-81.[Abstract/Free Full Text]
• Radke PW, Figulla HR, Drexler H. et al.; AACHEN Trial Investigators. A double-blind, randomized, placebo-controlled multicenter clinical trial to evaluate the effects of the angiotensin II receptor blocker candesartan cilexetil on intimal hyperplasia after coronary stent implantation. Am Heart J 2006;152:761.e1-6.[CrossRef][Medline] [Order article via Infotrieve]
• Yoshida O., Hirayama H., Nanasato M., Watanabe T., Murohara T. The angiotensin II receptor blocker candesartan cilexetil reduces neointima proliferation after coronary stent implantation: a prospective randomized study under intravascular ultrasound guidance. Am Heart J 2005;149:e2.[CrossRef][Medline] [Order article via Infotrieve]
• Wakeyama T., Ogawa H., Iida H. et al. Effects of candesartan and probucol on restenosis after coronary stenting: results of insight of stent intimal hyperplasia inhibition by new angiotensin II receptor antagonist (ISHIN) trial. Circ J 2003;67:519-24.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Iwata A., Miura S., Imaizumi S. et al. Do valsartan and losartan have the same effects in the treatment of coronary artery disease? Circ J 2007;71:31-8.
• Yokoyama J., Higuma T., Tomida H. et al. Impact of telmisartan on coronary stenting in patients with acute myocardial infarction compared with enalapril. Int J Cardiol 2008;(In press).
• Hong SJ, Shim WJ, Choi JI et al. Comparison of effects of telmisartan and valsartan on late lumen loss and inflammatory markers after sirolimus-eluting stent implantation in hypertensive patients. Am J Cardiol 2007;100:1625-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Schieffer B., Bünte C., Witte J. et al. Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am Coll Cardiol 2004; 44:362-8.[Abstract/Free Full Text]
• Barker TA, Massett MP, Korshunov VA, Mohan AM, Kennedy AJ, Berk BC Angiotensin II type 2 receptor expression after vascular injury. Differing effects of angiotensin-converting enzyme inhibition and angiotensin receptor blockade. Hypertension 2006;48:942-9.[Abstract/Free Full Text]
• Moriki N., Ito M., Seko T. et al. The effect of senescence of endothelial progenitor cells on in-stent restenosis in patients undergoing coronary stenting. Intern Med 2006; 45: 581-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Guerin P., Sauzeau V., Rolli-Derkinderen M. et al. Stent implantation activates RhoA in human arteries: inhibitory effect of rapamycin. J Vasc Res 2005;42:21-8.[CrossRef][Medline] [Order article via Infotrieve]
• Ohtani K., Egashira K., Ihara Y. et al. Angiotensin II type 1 receptor blockade attenuates in-stent restenosis by inhibiting inflammation and progenitor cells. Hypertension 2006;48: 664-70.[Abstract/Free Full Text]
• Cohn JN, Anand IS, Latini R., Masson S., Chiang YT, Glazer R.; Valsartan Heart Failure Trial Investigators. Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial. Circulation 2003;108:1306-09.[Abstract/Free Full Text]
• Amano T., Matsubara T., Izawa H. et al. Impact of plasma aldosterone levels for prediction of in-stent restenosis. Am J Cardiol 2006;97:785-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Adriaenssens T., Mehilli J., Wessely R. et al. Does addition of estradiol improve the efficacy of a rapamycin-eluting stent? Results of the ISAR-PEACE randomized trial. J Am Coll Cardiol 2007;49:1265-71.[Abstract/Free Full Text]

Journal of Renin-Angiotensin-Aldosterone System, Vol. 10, No. 2, 91-95 (2009)
DOI: 10.1177/1470320308098591


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Scopus Google Scholar Articles by Peters, S. Articles by Richter, C. PubMed PubMed Citation Articles by Peters, S. Articles by Richter, C. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Social Bookmarking                         What's this?